Hostname: page-component-8448b6f56d-tj2md Total loading time: 0 Render date: 2024-04-24T19:32:09.136Z Has data issue: false hasContentIssue false
  • English
  • Français

Non-uniform Response to Temozolomide Therapy in a Pituitary Gonadotroph Adenoma

Published online by Cambridge University Press:  02 December 2014

Ayca Ersen ,
Luis V. Syro ,
Luis C. Penagos ,
Humberto Uribe ,
Bernd W. Scheithauer deceased ,
Leon D. Ortiz ,
Fabio Rotondo ,
Eva Horvath  and
Kalman Kovacs
Ayca Ersen
Affiliation:
Dokuz Eylul University, Izmir, Turkey
Luis V. Syro
Affiliation:
Hospital Pablo Tobon Uribe and Clinica Medellin Medellin, Colombia Email: lvsyro@une.net.co
Luis C. Penagos
Affiliation:
Hospital Pablo Tobon Uribe and Clinica Medellin Medellin, Colombia Email: lvsyro@une.net.co
Humberto Uribe
Affiliation:
Clinica SOMA, Medellin, Colombia
Bernd W. Scheithauer deceased
Affiliation:
Mayo Clinic, Rochester, MN, USA
Leon D. Ortiz
Affiliation:
Instituto de Cancerologia, Clinica Las Americas, Medellin, Colombia
Fabio Rotondo
Affiliation:
St. Michael's Hospital. University of Toronto Toronto, Ontario, Canada
Eva Horvath
Affiliation:
St. Michael's Hospital. University of Toronto Toronto, Ontario, Canada
Kalman Kovacs
Affiliation:
St. Michael's Hospital. University of Toronto Toronto, Ontario, Canada
Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Letters to the Editor
Information
Canadian Journal of Neurological Sciences , Volume 39 , Issue 5 , September 2012 , pp. 683 - 685
Copyright
Copyright © The Canadian Journal of Neurological 2012

References

1.Heaney, AP.Clinical review: Pituitary carcinoma: difficult diagnosis and treatment. J Clin Endocrinol Metab. 2011;96(12):3649–60.Google Scholar
2.Ortiz, LD, Syro, LV, Scheithauer, BW, et al.Temozolomide in aggressive pituitary adenomas and carcinomas. Clinics (Sao Paulo). 2012;67 Suppl 1:119–23.Google Scholar
3.McCormack, AI, Wass, JA, Grossman, AB.Aggressive pituitary tumours: the role of temozolomide and the assessment of MGMT status Eur J Clin Invest. 2011;41(10):1133–48.Google Scholar
4.Syro, LV, Uribe, H, Penagos, LC, et al.Antitumour effects of temozolomide in a man with a large, invasive prolactinproducing pituitary neoplasm Clin Endocrinol. 2006;65(4):552–3.Google Scholar
5.Raverot, G, Sturm, N, de Fraipont, F, et al.Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience. J Clin Endocrinol Metab. 2010;95(10):4592–9.Google Scholar